In the article by Cheng et al, “Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association,” which published ahead of print on April 18, 2024, and ...
Background Japanese guidelines recommend a corticosteroid maintenance dose of 5–10 mg/day for cardiac sarcoidosis (CS); however, the optimal dose remains unclear. This study aimed to evaluate the ...
Myocarditis is an inflammatory disease of the heart that may occur because of infections, immune system activation, or exposure to drugs. The diagnosis of myocarditis has changed due to the ...
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine ...
The Foundation for Sarcoidosis Research (FSR) has been named a 2025 RareVoice Awards recipient by EveryLife Foundation for Rare Diseases, earning national recognition for Federal Advocacy by a Patient ...
Microbial involvement in sarcoidosis pathogenesis is suggested by the observation that histological findings in sarcoid granulomas are like those of leprosy, tuberculosis and parasitic infection. Some ...
Sarcoidosis remains one of the most compelling unresolved clinical challenges. It is defined by non-caseating granulomatous inflammation and remarkable clinical heterogeneity (1, 2), but still lacks a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results